Protagonist Therapeutics(PTGX)

Search documents
Protagonist Therapeutics (PTGX) Investor Presentation - Slideshow
2023-01-11 18:59
COMPANY OVERVIEW Dinesh V. Patel, PhD | President & CEO January 2023 1 Forward-looking Statements This presentation and the accompanying oral presentation contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, product candidates, capit ...
Protagonist Therapeutics(PTGX) - 2022 Q3 - Quarterly Report
2022-11-08 21:57
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-37852 PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 98-0505495 (State o ...
Protagonist Therapeutics (PTGX) Investor Presentation - Slideshow
2022-08-05 20:04
1 COMPANY OVERVIEW Dinesh V. Patel, PhD | President & CEO August 4, 2022 This presentation and the accompanying oral presentation contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, product candidates, capital resources, potential m ...
Protagonist Therapeutics(PTGX) - 2022 Q2 - Quarterly Report
2022-08-04 20:58
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-37852 PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 98-0505495 (State or oth ...
Protagonist Therapeutics (PTGX) Presents At Jefferies Healthcare Conference - Slideshow
2022-06-15 15:55
1 Jefferies Global Healthcare Conference Dinesh V. Patel, PhD | President & CEO June 8, 2022 This presentation and the accompanying oral presentation contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, product candidates, capital re ...
Protagonist Therapeutics (PTGX) Presents at Digestive Disease Week (DDW) 2022
2022-05-31 15:39
| --- | --- | --- | --- | |------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|-------|-------| | | | | | | | | | | | A Phase 2 randomized, double-blind, placebocontrolled, multi-center study to evaluate the | | | | | safety and efficacy of the oral, gut-restricted ɑ4β 7 integrin peptide antagonist PN-943 in ...
Protagonist Therapeutics(PTGX) - 2022 Q1 - Quarterly Report
2022-05-05 20:50
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-37852 PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of ...
Protagonist Therapeutics(PTGX) - 2021 Q4 - Annual Report
2022-02-28 21:50
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-37852 PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 98-0505495 (State or other j ...
Protagonist Therapeutics (PTGX) Investor Presentation - Slideshow
2022-01-11 20:02
1 COMPANY OVERVIEW Dinesh V. Patel, PhD | President & CEO January 2022 Forward-looking Statements This presentation and the accompanying oral presentation contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, product candidates, capit ...
Protagonist Therapeutics (PTGX) Investor Presentation - Slideshow
2021-12-09 20:23
8 Protagonist 1 COMPANY OVERVIEW December 2021 Dinesh V. Patel, PhD President & CEO Forward-looking Statements This presentation and the accompanying oral presentation contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, product cand ...